Pillar Biosciences Teams Up with Hamilton Company for Enhanced NGS Automation Solutions
Businesses and researchers will greatly benefit from this collaboration due to the combination of our advanced NGS products with Hamilton's efficient automation systems. This partnership aims to expedite tumor profiling results, which are critical for clinical decision-making, all while lowering labor costs and improving overall workflow efficiency.
The scope of this partnership is ambitious, initially targeting markets across North America, Central America, South America, New Zealand, and all Asia-Pacific countries. By leveraging Hamilton's extensive distribution and operational capabilities, Pillar Biosciences aims to ensure that more healthcare providers can access high-quality NGS testing solutions.
Michael Mouradian, Vice President of Scientific Strategy and Market Development at Hamilton, expressed enthusiasm for the collaboration, recognizing the potential to provide users with a more accessible NGS testing process. “Our proven automation technology, when combined with Pillar’s groundbreaking NGS solutions, positions us uniquely to meet the growing demand for efficient and accurate testing in cancer diagnostics,” he stated.
Next-generation sequencing has revolutionized the field of cancer diagnostics by providing comprehensive insights into the genetic makeup of tumors. Pillar Biosciences specializes in developing precise and sensitive NGS testing technologies that play a crucial role in identifying the best therapeutic options for cancer patients. Their proprietary SLIMamp® and PiVAT® technologies enhance the localization and reduce the cost of testing, facilitating better access for clinicians and patients alike.
The collaboration with Hamilton represents a significant advancement towards achieving efficiency in NGS testing. With over 20 NGS testing kits in various formats developed by Pillar and innovative automation solutions from Hamilton, the partnership anticipates improving testing workflows significantly.
Pillar Biosciences is fundamentally focused on Decision Medicine™, which aims to optimize therapy selection for patients through accurate NGS testing. With their main operations based in Natick, Massachusetts, the company is committed to expanding its range of products and enhancing the accessibility of their NGS solutions globally.
Hamilton Company, headquartered in Reno, Nevada, with facilities in Massachusetts and Switzerland, is renowned for its design and manufacturing of liquid handling and robotics solutions. The company’s legacy of precision and quality, and its ISO 9001 Certification underline its commitment to excellence in automation for laboratory processes.
In summary, the collaboration between Pillar Biosciences and Hamilton Company symbolizes a transformative step in the world of NGS testing. By streamlining automation and enhancing accessibility, they aim to eliminate barriers that have traditionally hindered localized NGS testing. Clinicians and researchers can anticipate a future where rapid, efficient, and cost-effective testing becomes a standard in cancer diagnostics.
A Global Vision
The scope of this partnership is ambitious, initially targeting markets across North America, Central America, South America, New Zealand, and all Asia-Pacific countries. By leveraging Hamilton's extensive distribution and operational capabilities, Pillar Biosciences aims to ensure that more healthcare providers can access high-quality NGS testing solutions.
Michael Mouradian, Vice President of Scientific Strategy and Market Development at Hamilton, expressed enthusiasm for the collaboration, recognizing the potential to provide users with a more accessible NGS testing process. “Our proven automation technology, when combined with Pillar’s groundbreaking NGS solutions, positions us uniquely to meet the growing demand for efficient and accurate testing in cancer diagnostics,” he stated.
The Importance of NGS Testing
Next-generation sequencing has revolutionized the field of cancer diagnostics by providing comprehensive insights into the genetic makeup of tumors. Pillar Biosciences specializes in developing precise and sensitive NGS testing technologies that play a crucial role in identifying the best therapeutic options for cancer patients. Their proprietary SLIMamp® and PiVAT® technologies enhance the localization and reduce the cost of testing, facilitating better access for clinicians and patients alike.
The collaboration with Hamilton represents a significant advancement towards achieving efficiency in NGS testing. With over 20 NGS testing kits in various formats developed by Pillar and innovative automation solutions from Hamilton, the partnership anticipates improving testing workflows significantly.
About the Companies
Pillar Biosciences is fundamentally focused on Decision Medicine™, which aims to optimize therapy selection for patients through accurate NGS testing. With their main operations based in Natick, Massachusetts, the company is committed to expanding its range of products and enhancing the accessibility of their NGS solutions globally.
Hamilton Company, headquartered in Reno, Nevada, with facilities in Massachusetts and Switzerland, is renowned for its design and manufacturing of liquid handling and robotics solutions. The company’s legacy of precision and quality, and its ISO 9001 Certification underline its commitment to excellence in automation for laboratory processes.
Conclusion
In summary, the collaboration between Pillar Biosciences and Hamilton Company symbolizes a transformative step in the world of NGS testing. By streamlining automation and enhancing accessibility, they aim to eliminate barriers that have traditionally hindered localized NGS testing. Clinicians and researchers can anticipate a future where rapid, efficient, and cost-effective testing becomes a standard in cancer diagnostics.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.